Table 2.
LECW and medication management of heart failure during admission and at discharge for Control and Intervention groups.
| Overall | Control | Intervention | p | |
|---|---|---|---|---|
| n | 29 | 19 | 10 | |
| Time LECW applied - hours (mean (SD)) | 0 (0) | 89 (49) | ||
| % time with LECW applied (mean (SD)) | 0 (0) | 80 (3) | ||
| IV Diuretic type escalated (n (%)) | 5 (17.2) | 5 (26.3) | 0 (0.0) | 0.079 |
| IV Diuretic continuous infusion used (n (%)) | 7 (24.1) | 7 (36.8) | 0 (0.0) | 0.028 |
| Adjuvant diuretic used (n (%)) | 3 (10.3) | 3 (15.8) | 0 (0) | 0.198 |
| Daily dose of IV diuresis – mg (median (IQR))+ | 160 (80–160) | 140 (80–160) | 160 (80–160) | 0.789 |
| Total IV diuresis - mg (median (IQR))+ | 480 (400–800) | 440 (400–800) | 480 (380–420) | 0.801 |
| PO Diuretic type on discharge (n (%)) | 0.366 | |||
| Furosemide | 15 (51.7) | 11 (57.9) | 4 (40.0) | |
| Bumetanide | 12 (41.4) | 7 (36.8) | 5 (50.0) | |
| Torsemide | 1 (3.4) | 0 (0.0) | 1 (10.0) | |
| Hydrochlorothiazide | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Spironolactone on discharge (n (%)) | 14 (48.3) | 7 (36.8) | 7 (70.0) | 0.096 |
LECW: lower extremity compression wraps; IV: intravenous; PO: oral; mg: milligrams.
+Reported in furosemide equivalent doses.
Bolded p-values indicate statistically significant values < 0.05.